Roland Repp

Kiel, SH, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia.

Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia.

Journal: British journal of haematology
Published: August 22, 2025

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.

Journal: British journal of haematology
Published: May 07, 2025

Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.

Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.

Journal: Leukemia
Published: April 03, 2025

Allogeneic Hematopoietic Stem Cell Transplantation From a CD36+ Donor in an Immunized Patient With Type I Hereditary CD36 Deficiency.

Allogeneic Hematopoietic Stem Cell Transplantation From a CD36+ Donor in an Immunized Patient With Type I Hereditary CD36 Deficiency.

Journal: Transplantation
Published: February 28, 2025

High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia.

High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia.

Journal: British journal of haematology
Published: November 25, 2024

Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Journal: Blood advances
Published: April 03, 2024

Adoptive transfer of donor B lymphocytes: a phase 1/2a study for patients after allogeneic stem cell transplantation.

Adoptive transfer of donor B lymphocytes: a phase 1/2a study for patients after allogeneic stem cell transplantation.

Journal: Blood advances
Published: December 11, 2023

Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease.

Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease.

Journal: Bone marrow transplantation
Published: December 31, 2022

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.

Journal: Leukemia
Published: July 07, 2020

Dental status does not predict infection during stem cell transplantation: a single-center survey.

Dental status does not predict infection during stem cell transplantation: a single-center survey.

Journal: Bone marrow transplantation
Published: May 09, 2017

Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment.

Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment.

Journal: Science immunology
Published: August 09, 2016

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Journal: The Lancet. Oncology
Published: July 20, 2015
Showing 1-12 of 22

Last Updated: 09/26/2026